Bezuclastinib's registrational trial meets predefined success criteria, with a big spotlight on toxicity.

ADCs newly into human trials include Lilly's PTK7 and two bispecifics.

Lynozyfic could have an edge over rival BCMA-targeting bispecifics.

Some big deals in the second quarter have raised hopes that takeouts are back.

Zegfrovy is approved in a best-case setting, but Dizal has no US presence.

Controversial nods came for Urogen’s Zusduri and Astra/Daiichi’s Datroway.